Related Experiment Video

Updated: Jul 28, 2025

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
06:07

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors

Published on: August 5, 2022

2.7K

The role of m6A methylation in therapy resistance in cancer

Hengzhao Zhuang1, Bo Yu2, Dan Tao3

  • 1Department of Radiation Oncology, The First Affiliated Hospital of Soochow University, Suzhou, 21500, China.

Molecular Cancer
|June 1, 2023
PubMed

Insights

N6-methyladenosine (m6A) RNA methylation influences cancer cell growth but its role in cancer therapy resistance remains unclear. This review summarizes current research on m6A

Area of Science:

  • Epigenetics
  • RNA biology
  • Cancer research

Background:

  • Cancer therapy resistance is a major obstacle in effective cancer treatment.
  • N6-methyladenosine (m6A) is a prevalent RNA modification impacting RNA metabolism.
  • m6A regulates cancer cell proliferation and invasion, but its role in therapy resistance is not well understood.

Purpose of the Study:

  • To review and summarize the current understanding of m6A's role in cancer therapy resistance.
  • To highlight the significance of m6A RNA methylation in overcoming treatment failure.

Main Methods:

  • Literature review of existing research on m6A and cancer therapy resistance.
  • Synthesis of findings from studies investigating m6A's impact on various cancer types and treatments.

Main Results:

  • m6A RNA methylation is implicated in various cellular processes relevant to cancer progression.
  • Evidence suggests m6A modifications play a crucial role in the development of resistance to cancer therapies.
  • Further research is needed to fully elucidate the mechanisms by which m6A influences therapy resistance.

Conclusions:

  • m6A RNA methylation is a critical factor in cancer therapy resistance.
  • Understanding m6A's function may lead to novel therapeutic strategies to overcome treatment failure.
  • Targeting m6A pathways could be a promising approach to improve cancer treatment outcomes.
Keywords:
CancerChemoresistanceRadiotherapy resistancem6A methylation

More Related Videos

Author Spotlight: Decoding RNA Methylation's Role in Pancreatic Cancer - A Single-Base Resolution Study06:57

Author Spotlight: Decoding RNA Methylation's Role in Pancreatic Cancer - A Single-Base Resolution Study

Published on: July 7, 2023

1.2K
A Method for Measuring RNA N6-methyladenosine Modifications in Cells and Tissues08:56

A Method for Measuring RNA N6-methyladenosine Modifications in Cells and Tissues

Published on: December 5, 2016

11.0K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Epigenetic Regulation01:46

Epigenetic Regulation

Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
31.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Phase II Reactions: Methylation Reactions01:17

Phase II Reactions: Methylation Reactions

Methylation is a phase II biotransformation process involving the attachment of a methyl group to a substrate. Enzymes known as methyltransferases orchestrate this reaction.
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
244
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K